Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | Chief Technical Ops Officer | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,085 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 7,651 · Balance 68,085 F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 9, 2026 21:53 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 7,651 | $60.36 | $461,814.36 |
DisclosureSEC source: 0001886794-26-000012 · wk-form4_1788990788.xml · nonDerivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,085 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2026 Filed Sep 2, 2026 23:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 659 | $61.58 | $40,581.22 |
DisclosureSEC source: 0001886794-26-000010 · wk-form4_1788393367.xml · nonDerivative · entry 2 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,736 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 23:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 361 | $60.74 | $21,927.14 |
DisclosureSEC source: 0001886794-26-000010 · wk-form4_1788393367.xml · nonDerivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,395 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| August 05, 2026 Filed Aug 5, 2026 23:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001886794-26-000008 · wk-form4_1785970896.xml · derivative · entry 3 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 17,000 shares Expires 2032-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| August 05, 2026 Filed Aug 5, 2026 23:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 17,000 | $55.00 | $935,068.00 |
DisclosureSEC source: 0001886794-26-000008 · wk-form4_1785970896.xml · nonDerivative · entry 2 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,756 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 6, 2026. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $55.00 to $55.255. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 05, 2026 Filed Aug 5, 2026 23:01 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 17,000 | $24.79 | $421,430.00 |
DisclosureSEC source: 0001886794-26-000008 · wk-form4_1785970896.xml · nonDerivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 780 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 604 | $59.32 | $35,829.28 |
DisclosureSEC source: 0001886794-26-000006 · wk-form4_1773264320.xml · nonDerivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,976 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 01:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 465 | $61.98 | $28,820.70 |
DisclosureSEC source: 0001886794-26-000004 · wk-form4_1772500026.xml · nonDerivative · entry 3 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,580 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 01:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 292 | $61.98 | $18,098.16 |
DisclosureSEC source: 0001886794-26-000004 · wk-form4_1772500026.xml · nonDerivative · entry 2 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,045 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 46,424 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0001886794-26-000004 · wk-form4_1772500026.xml · derivative · entry 4 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,424 Underlying: Common Stock · 46,424 shares Expires 2036-02-26 F3 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 53,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001886794-26-000004 · wk-form4_1772500026.xml · nonDerivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,337 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 21:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 9,743 | $46.69 | $454,890.93 |
DisclosureSEC source: 0001886794-26-000002 · wk-form4_1767388912.xml · nonDerivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,928 F1 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $46.42 to $47.155. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes one (1) share acquired on November 17, 2025 under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,204 | $32.41 | $39,021.64 |
DisclosureSEC source: 0001886794-25-000004 · wk-form4_1757536078.xml · nonDerivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,670 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 464 | $31.56 | $14,643.84 |
DisclosureSEC source: 0001886794-25-000003 · wk-form4_1757016729.xml · nonDerivative · entry 3 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,874 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 783 | $31.56 | $24,711.48 |
DisclosureSEC source: 0001886794-25-000003 · wk-form4_1757016729.xml · nonDerivative · entry 2 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,338 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 291 | $31.56 | $9,183.96 |
DisclosureSEC source: 0001886794-25-000003 · wk-form4_1757016729.xml · nonDerivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · Chief Technical Ops Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,121 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. F2 · balance_after: Includes 329 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $47.95 | $0.00 |
DisclosureSEC source: 0001209191-23-000966 · doc4.xml · derivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · SVP Cml Mfg & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-12-30 F1 · derivative.exercise_date: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 21:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,990 | $0.00 Strike: $25.06 | $0.00 |
DisclosureSEC source: 0001209191-22-062992 · doc4.xml · derivative · entry 2 Dhaliwal Harpreet S. · CIK 0001886794 · SVP Cml Mfg & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,010 Underlying: Common Stock · 3,990 shares Expires 2031-11-07 F2 · derivative.exercise_date: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 21:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,990 | $25.06 | $99,989.40 |
DisclosureSEC source: 0001209191-22-062992 · doc4.xml · nonDerivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · SVP Cml Mfg & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 928 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2022. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 20:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,513 | $26.38 | $39,912.94 |
DisclosureSEC source: 0001209191-22-049024 · doc4.xml · nonDerivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · SVP Cml Mfg & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,890 F1 · kind: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. F2 · balance_after: Includes 903 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 17, 2022. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-22-016523 · doc4.xml · derivative · entry 2 Dhaliwal Harpreet S. · CIK 0001886794 · SVP Cml Mfg & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-03-01 F2 · derivative.exercise_date: 1/48 of shares subject to the option vest on April 2, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 01:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016523 · doc4.xml · nonDerivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · SVP Cml Mfg & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2022 and 12.5% of the shares every six months thereafter. Read SEC document |
| November 08, 2021 Filed Feb 1, 2022 22:41 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $25.06 | $0.00 |
DisclosureSEC source: 0001209191-22-005978 · doc4.xml · derivative · entry 1 Dhaliwal Harpreet S. · CIK 0001886794 · SVP Cml Mfg & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-11-07 F1 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest on October 1, 2022, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.